The Pharmacology Core Facility provides support infrastructure for investigators conducting clinical pharmacology and biomarker research in the context of cancer clinical trials. We provide expertise in blood sample processing, measurement of drug concentrations, and pharmacokinetics.

Services provided help to evaluate the relationship between pharmacokinetics and toxicity for developing effective drug treatments with minimum side effects; determine the influence of genetics on drug response with the purpose of stratifying patients based on likelihood of benefit to treatment or treatment-induced toxicity; investigate potential pharmacokinetic drug-drug interactions that could cause adverse drug reactions or reduce the clinical efficacy of chemotherapy; and develop drug activity biomarkers such as pharmacodynamic or predictive markers that predict the physiological impact of treatment or tumor response.


Acknowledgement of core facility contributions in publications is appreciated.


Cancer Center members should cite the Cancer Center Support Grant (P30CA014599) when publishing any work assisted by this core facility.